Want to see ADOCY full AI Analyst Report?

Adocia (ADOCY) Price & Analysis

16 Followers

ADOCY Stock Chart & Stats

$4.64

$0.00(0.00%)

At close: Sep 01 4:00 PM EDT

$4.64

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$4.09 - $12.55

Previous CloseN/A

Volume11.00

Average Volume (3M)0.00

Market Cap

$82.69M

Enterprise Value$137.13

Total Cash (Recent Filing)$17.25M

Total Debt (Recent Filing)$8.90M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Sep 24, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.87

Shares Outstanding20,253,056

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.55

Price to Book (P/B)132.14

Price to Sales (P/S)139.00

P/FCF Ratio-30.16

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.68

Revenue Forecast (FY)$16.43M

Bulls Say, Bears Say

Bulls Say

Proprietary Formulation PlatformAdocia’s proprietary formulation and delivery technologies provide a platform for improving established active ingredients and creating differentiated therapeutic profiles. This can support multiple diabetes and injectable programs, creating recurring partnering opportunities beyond a single drug candidate or indication.

Strong Gross Margins In Recent YearsStrong gross margins in several recent years indicate that Adocia’s underlying technology and development work can generate attractive economics when revenue is recognized. If partnering activity becomes more consistent, this gross-profit potential could help convert future milestone or licensing revenue into operating leverage.

Improved Operating Cash BurnThe material narrowing of operating cash outflow in 2025 is a constructive sign for cost control and financial discipline. Positive equity also improves the capital structure relative to prior periods, although the company still needs to reduce recurring cash consumption to make this improvement durable.

Bears Say

Persistent UnprofitabilityPersistent net losses and an extremely negative 2025 margin show that current revenue and gross profit are insufficient to cover Adocia’s operating cost base. Continued losses can consume capital, limit investment flexibility, and make sustainable earnings dependent on successful future partnering or commercialization.

Highly Volatile RevenueThe sharp revenue decline after a strong prior year demonstrates that Adocia’s financial performance is uneven and likely dependent on the timing of partnerships, milestones, or other development-related receipts. Such volatility reduces earnings visibility and complicates planning, budgeting, and long-term capital allocation.

High Leverage And Ongoing Cash BurnHigh debt relative to equity leaves Adocia with limited protection if losses persist, while recurring negative operating and free cash flow indicates continued funding needs. This combination can constrain research investment and increase dependence on external financing or successful partner payments.

ADOCY FAQ

What was Adocia SA’s price range in the past 12 months?

Adocia SA lowest stock price was $4.09 and its highest was $12.55 in the past 12 months.

What is Adocia SA’s market cap?

Adocia SA’s market cap is $82.69M.

When is Adocia SA’s upcoming earnings report date?

Adocia SA’s upcoming earnings report date is Sep 24, 2026 which is in 8 days.

How were Adocia SA’s earnings last quarter?

Adocia SA released its earnings results on Apr 21, 2026. The company reported -$0.453 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.22.

Is Adocia SA overvalued?

According to Wall Street analysts Adocia SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Adocia SA pay dividends?

Adocia SA does not currently pay dividends.

What is Adocia SA’s EPS estimate?

Adocia SA’s EPS estimate is -0.5.

How many shares outstanding does Adocia SA have?

Adocia SA has 20,253,056 shares outstanding.

What happened to Adocia SA’s price movement after its last earnings report?

Adocia SA reported an EPS of -$0.453 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went up 16.641%.

Which hedge fund is a major shareholder of Adocia SA?

Currently, no hedge funds are holding shares in ADOCY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Adocia SA

Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders. Central to its work is the exclusive BioChaperone technological platform, engineered to significantly enhance the performance characteristics of therapeutic proteins. Its robust clinical pipeline features several advanced candidates: Insulin-based treatments: Including BioChaperone Lispro U100 and U200, which are ultra-fast-acting versions derived from rapid insulin lispro; BioChaperone Combo, combining long-acting insulin glargine with rapid-acting insulin lispro; and BioChaperone LisPram, which pairs prandial insulin with pramlintide. Hypoglycemia treatment: BioChaperone Glucagon, an aqueous human glucagon solution specifically designed to manage severe low blood sugar episodes. Other: M1Pram, a derivative combining insulin glargine and pramlintide. The preclinical development programs further expand into bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a co-formulation of insulin glargine and a GLP-1 receptor analogue. Additionally, its preclinical portfolio targets obesity with multi-hormonal products like BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a tripartite blend of pramlintide, glucagon, and exenatide. Adocia has forged a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. for the development and market introduction of BioChaperone Lispro and BioChaperone Combo across China, other parts of Asia, and the Middle East. Established in 2005, the company maintains its headquarters in Lyon, France.